AZTherapies Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 16

Employees
  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 17

AZTherapies General Information

Description

Operator of a biopharmaceutical company intended to offer treatment for multiple neurodegenerations and neuroinflammation-related CNS diseases. The company offers a novel multi-action combination drug regimen that is used to modify disease progression by slowing down or halting Alzheimer's disease early in its development, enabling healthcare providers to easily cure Alzheimer's patients without any surgery.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 200 Clarendon Street
  • 17th Floor
  • Boston, MA 02116
  • United States
+1 (617) 000-0000

AZTherapies Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AZTherapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 01-Sep-2021 00000 Completed Clinical Trials - Phase 3
7. Later Stage VC (Series C1) 29-Sep-2020 000.00 00000 00000 Completed Clinical Trials - Phase 3
6. Debt - PPP 19-May-2020 000.00 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 31-Jan-2020 000.00 000.00 00000 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 16-Oct-2018 000.00 000.00 00000 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series A) 0000 000.00 00000 Completed Clinical Trials - Phase 3
2. Later Stage VC (Series A) 06-Feb-2017 $16.4M $26.4M 00000 Completed Clinical Trials - Phase 3
1. Early Stage VC 06-Jan-2015 $10M $10M Completed Clinical Trials - Phase 3
To view AZTherapies’s complete valuation and funding history, request access »

AZTherapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C1 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
Series A-1 2,084,052 $0.000100 $3.33 $3.33 1x $3.33 3.8%
Series A 4,212,559 $0.000100 $4 $4 1x $4 7.69%
To view AZTherapies’s complete cap table history, request access »

AZTherapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to offer treatment for multiple neurodegenerations and neuroinflammatio
Drug Discovery
Boston, MA
16 As of 2023
00000
00000000000 00000

000000

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000 000000000
Framingham, MA
00 As of 0000
000.00
00000000000 000.00

000000

it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidata
0000 000000000
San Carlos, CA
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AZTherapies Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alzheon Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
0000000 Venture Capital-Backed San Carlos, CA 00 000.00 00000000000 000.00
000 000000000000 Venture Capital-Backed Durham, NC 00 000.00 00000000000 000.00
000000000000 Venture Capital-Backed Clarksville, MD 0 00.000 00000000000
00000 000000000000 Formerly VC-backed Grand Rapids, MI 0 0000 000000&0 0000
You’re viewing 5 of 48 competitors. Get the full list »

AZTherapies Patents

AZTherapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019242381-A1 Car-treg-based therapies for treating neurodegenerative diseases Pending 27-Mar-2018 000000000
CA-3095298-A1 Car-treg-based therapies for treating neurodegenerative diseases Pending 27-Mar-2018 000000000
EP-3773629-A1 Car-treg-based therapies for treating neurodegenerative diseases Pending 27-Mar-2018 000000000
EP-3773629-A4 Car-treg-based therapies for treating neurodegenerative diseases Pending 27-Mar-2018 000000000 0
US-20210023137-A1 Car-treg-based therapies for treating neurodegenerative diseases Pending 27-Mar-2018 A61K35/17
To view AZTherapies’s complete patent history, request access »

AZTherapies Executive Team (9)

Name Title Board Seat Contact Info
George Alex Interim Chief Executive Officer
Karen Reeves MD President & Chief Medical Officer
David Elmaleh Ph.D Scientific Founder, Executive Chairman & Chief Scientific Officer
You’re viewing 3 of 9 executive team members. Get the full list »

AZTherapies Board Members (13)

Name Representing Role Since
David Elmaleh Ph.D AZTherapies Scientific Founder, Executive Chairman & Chief Scientific Officer 000 0000
David King Self Board Member & Business Advisor 000 0000
David Taft Self Board Member 000 0000
George Behrakis AZTherapies Board Member 000 0000
Gillian Sandler Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

AZTherapies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AZTherapies Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Black Granite Capital Growth/Expansion Minority 000 0000 000000 0
Catalytic Impact Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
DEFTA Partners Venture Capital Minority 000 0000 000000 0
Duopharma Biotech PE-Backed Company Minority 000 0000 000000 0
Wooshin Venture Investment Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

AZTherapies Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 24-Oct-2019 0000000000 Biotechnology 00000 000
To view AZTherapies’s complete acquisitions history, request access »